Recent news on Daclizumab

Biogen's Measured Growth  -  May 2, 2007
Motley FoolThough BG-12 and daclizumab may have some promise in extending Biogen's reach in the MS market, it will be years before either of them could launch.

Renal transplantation in 1-5 year olds  -  26 Apr 2007
News-Medical.net,In the last 21 cases, basiliximab or daclizumab was added. The group found that there were 13 (32.5%) graft losses. Four of these had artery/vein thromboses

PDL Biopharma Patent Claims Upheld  -  Apr 24, 2007
Forbes,The patent covers several of the company's products, including daclizumab which is currently in mid-stage studies as a multiple sclerosis treatment.

Renal Transplantation In Children Younger Than 6 Years Old  -  Apr 23, 2007
Medical News Today (press release),In the last 21 cases, basiliximab or daclizumab was added. The group found that there were 13 (32.5%) graft losses. Four of these had artery/vein thromboses

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 25, 2007
Financial News USA (press release),...that contain amino acid substitutions made under PDL's antibody humanization technology and provides specific coverage for our daclizumab antibody.

Third Point's Potshots  -  Apr 13, 2007
Motley Fool...it also brought one of the top multiple sclerosis companies in the world on board with the development of PDL's MS drug candidate, daclizumab.

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Yahoo! News (press release)These increases were due primarily to higher clinical development expenses, particularly for the company's Nuvion® antibody product and daclizumab,

Study Tests Oral Insulin To Prevent Type 1 Diabetes  -  Feb 4, 2007
Medical News Today (press release),Also under way is a study testing whether mycophenolate mofetil (MMF) or MMF plus daclizumab (DZB), drugs approved by FDA to prevent rejection after an

Clinical study of oral insulin's efficacy against type 1 diabetes ...  -  Feb 1, 2007
DailyIndia.com,Also under way is a study testing whether mycophenolate mofetil (MMF) or MMF plus daclizumab (DZB), drugs to prevent rejection after an organ transplant,

Roche Says Goodbye to PDL  -  Nov 27, 2006
MSNBCOn Tuesday, Motley Fool Rule Breakers pick PDL BioPharma(Nasdaq: PDLI) suffered a setback for its drug candidate daclizumab, revealing that partner Roche

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)Daclizumab, a humanized monoclonal antibody, binds to the alpha chain of the interleukin (IL)-2 receptor. Rose and colleagues [11] described results from a

Biotech Has Lackluster Month of November  -  Dec 1, 2006
PR Newswire (press release),Although PDL BioPharma, Inc. said that Roche would discontinue its agreement to jointly develop and commercialize daclizumab for organ transplant patients

PDL BioPharma Q3 2006 Earnings Call Transcript  Nov 3, 2006
...quarter through a combination of ongoing expense management and disciplined R&D decisions, particularly regarding the Ularitide and Daclizumab asthma programs. ... -Seeking Alpha, Mixed Feelings About PDL  Nov 6, 2006
PDL had a small setback this quarter with its pipeline when its partner, Roche, decided to discontinue the co-development of Daclizumab for asthma. ... -Motley Fool PDL BioPharma Announces Third Quarter 2006 Financial Results  Nov 2, 2006
...in deferred licensing, collaboration and other revenues recognized as a result of the discontinuation of the Roche collaboration for daclizumab in asthma. ... -Earthtimes.org PDL BioPharma Trims 3Q Loss  Nov 2, 2006
A large portion of the increase came from a $18.8 million gain when the company ended its collaboration with Roche on daclizumab for asthma. ... -MSN Money Micromet Presents New Anti-IL-2 Antibody with Unique Mode of ...  Oct 25, 2006
The inhibitory effect of MT204 was studied in vitro in comparison to Zenapax(R) (daclizumab), a marketed therapeutic antibody, which interferes with the IL-2 ... -PharmaLive.com (press release), PDL BioPharma Announces Roche to Discontinue Co-Development of ...  -  12 Dec 2006
PharmaLive.com (press release),This decision follows another decision by Roche earlier this year to discontinue its involvement in the co-development of daclizumab for the treatment of

Biotech Has Lackluster Month of November  -  12 Dec 2006
PR Newswire (press release),Although PDL BioPharma, Inc. said that Roche would discontinue its agreement to jointly develop and commercialize daclizumab for organ transplant patients

Stocks to Watch: Alcoa, Dell, General Motors, Mattel, Verisign  -  12 Dec 2006
Minyanville.com,PDL BioPharma (PDLI) said Roche (RHHGY) will discontinue its agreement with PDL to jointly develop daclizumab for organ transplant patients on longer-term

(PRN) - Georgia DOT Crews Plant Bulbs as Part of Wildflower ...  -  12 Dec 2006
Bolsamania.com,...(PRN) - PDL BioPharma Announces Roche to Discontinue Co-Development of Daclizumab ... [+]. (PRN) - Spark Networks(R) Announces Results of Its Annual General

Stocks May Meander In A Day Of Light Activity; Earnings Likely To ...  -  12 Dec 2006
Trading Markets,...could give back some ground after it revealed that Roche Holding has pulled out of a partnership to develop the organ transplant therapy daclizumab.

PDL BioPharma Announces Roche To Discontinue Co-Development Of ...  -  Nov 22, 2006
Medical News Today (press release),PDL BioPharma, Inc. (Nasdaq: PDLI) announced today that Roche will discontinue its agreement with PDL to jointly develop and commercialize daclizumab for

Roche Gives Up Daclizumab; PDL Seeking Asthma Partner  -  Nov 22, 2006
BioWorld Online,Hoffmann-La Roche Inc.'s decision to back out entirely of the deal with PDL BioPharma Inc. for Zenapax (daclizumab) leaves intact the biotech firm's main

Roche Terminates Daclizumab Deal with PDL BioPharma  -  Nov 22, 2006
Genetic Engineering News (press release),Roche discontinued its agreement with PDL BioPharma to jointly develop and commercialize Daclizumab for organ transplant patients. Roche made this decision

Roche ends transplant collaboration with PDL  -  Nov 22, 2006
Pharmaceutical Business ReviewRoche has discontinued its collaboration with PDL BioPharma over the drug daclizumab for organ transplant patients after an internal review of its

UPDATE 1-PDL says Roche ends organ transplant drug venture  -  Nov 21, 2006
ReutersVX: Quote, Profile, Research) will discontinue its agreement with PDL to jointly develop and commercialize the experimental drug daclizumab for organ

Market Report -- In Play (PDLI)  -  Nov 21, 2006
MSN MoneyPDL BioPharma Announces Roche to Discontinue Co-Development of Daclizumab Co announced that Roche will discontinue its agreement with PDL to jointly develop

Roche Says Goodbye to PDL  -  Nov 27, 2006
MSNBCOn Tuesday, Motley Fool Rule Breakers pick PDL BioPharma(Nasdaq: PDLI) suffered a setback for its drug candidate daclizumab, revealing that partner Roche

Roche ends agreement with PDL BioPharma  -  Nov 23, 2006
Bizjournals.com,In August, Roche ended its part in developing daclizumab for use in treating asthma. The two companies had been working together on the drug since 2004.

Gilead Sciences to Present at Two Upcoming Investor Conferences ...  -  Nov 24, 2006
Financial News USA (press release),PDL BioPharma Inc. (Nasdaq:PDLI) after Tuesday's closing bell said Roche will discontinue its agreement with PDL to jointly develop daclizumab for organ

Roche Ends PDL BioPharma Pact  -  Nov 22, 2006
TheStreet.com...based biopharmaceutical company, said that Swiss Roche will discontinue its agreement with PDL to jointly develop and commercialize daclizumab for organ

PDL BioPharma Inc. Traded Lower After Being Dumped By Roche  -  Nov 22, 2006
Trading Markets,Further, Roche discontinue its involvement in the co-development of daclizumab for the treatment of asthma earlier this year following the decision.

Roche pulls out of PDL collaboration  -  Nov 21, 2006
BusinessWeekDrug developer PDL BioPharma Inc. said Tuesday Swiss drug maker Roche Holding AG pulled out of their partnership on to develop daclizumab as an organ

Roche Pulls Out of PDL Collaboration  -  Nov 21, 2006
MSN Money...(AP) - Drug developer PDL BioPharma Inc. said Tuesday Swiss drug maker Roche Holding AG pulled out of their partnership on to develop daclizumab as an organ

PDL BioPharma Hits Multi-Month High  -  Nov 24, 2006
Trading Markets,Late Tuesday, the company reported that Roche will discontinue co-developing the drug, Daclizumab. PDL BioPharma's shares are now up 61 cents to trade at

Analyst upgrades 11-22-06: Advanced Medical gets a quad downgrade  -  Nov 22, 2006
Blogging Stocks...to Underperform from Neutral after news of Hoffman-LaRoche (RHHBY) discontinuing the co-development of Daclizumab for organ transplant patients.

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)Daclizumab, a humanized monoclonal antibody, binds to the alpha chain of the interleukin (IL)-2 receptor. Rose and colleagues [11] described results from a

US Stocks Gain as Earnings at Dell and Brocade Beat Estimates  -  Nov 22, 2006
BloombergPDL BioPharma Inc. fell $1.40 to $21.27 after saying Roche Holding AG is discontinuing their agreement to jointly develop and sell daclizumab,

US Stock-Index Futures Advance After Dell Beats Estimates  -  Nov 22, 2006
BloombergPDL BioPharma Inc. lost $1.40 to $21.27 after the company said Roche Holding AG is discontinuing their agreement to jointly develop and sell daclizumab,

US Stock-Index Futures Advance After Dell Beats Estimates  -  Nov 22, 2006
BloombergPDL BioPharma Inc. lost $1.43 to $21.24 after the company said Roche Holding AG is discontinuing their agreement to jointly develop and sell daclizumab,

Eye On Stocks For Wednesday, Nov. 22, 2006  -  Nov 21, 2006
Forbes,...in the extended trading session after the tiny biotech said Roche decided to end co-development of experimental multiple sclerosis treatment daclizumab.

StreetInsider.com Pre-Open Movers 11/22  -  Nov 22, 2006
StreetInsider.com (subscription),PDL BioPharma, Inc. (Nasdaq: PDLI) 4% LOWER; announced that Roche will discontinue its agreement with PDL to jointly develop and commercialize daclizumab

Stocks Pause For A Breather In Holiday Shortened Week  -  Nov 25, 2006
Trading Markets,...news | PowerRating) eased 0.71% after it revealed that Roche Holding has pulled out of a partnership to develop the organ transplant therapy daclizumab.

Liver-Kidney Transplantation Stands Test of Time  Aug 23, 2006
...demonstrated the benefit of a new kidney-sparing protocol using an immunosuppression regimen with Simulect (basiliximab) Zenapax (daclizumab) that protected ... -MedPage Today

Report Describes Near-Fatal Course of TGN1412-Exposed Test ...  Aug 14, 2006
...to the ICU where they received cardiopulmonary support, high-dose steroid therapy, and treatment with an anti-IL-2 receptor antagonist antibody, daclizumab. ... -Medscape (subscription)

Biogen Idec Q2 2006 Earnings Conference Call Transcript (BIIB)  Jul 26, 2006
An efficacious oral therapy was built upon the success of AVONEX and enhanced our pipeline of potential MS therapies such as TYSABRI, RITUXAN and daclizumab. ... -Seeking Alpha

Low-Dose Tacrolimus Appear to Fare Best in Symphony Trial ...  Jul 26, 2006
Patients were also treated with mycophenolate mofetil and steroids, and underwent induction treatment with daclizumab, said presenter Henrik Ekberg, MD ... -DG News

PDL BioPharma Announces Second Quarter 2006 Financial Results  Aug 3, 2006
...year. The increase reflected expanded clinical development activities associated with the ularitide, Nuvion and daclizumab programs. ... -Yahoo! News



PDL BioPharma Announces First Quarter 2006 Financial Results  May 2, 2006
The increase reflected expanded clinical development activities for daclizumab in MS and asthma, for the newly initiated Phase 2/3 study of Nuvion, for scale ... - MSN Money

NICE Issues Guidance On Immunosuppressive Therapy For Young Kidney ...  Apr 27, 2006
..._Basiliximab or daclizumab are recommended as ... The less expensive of the two drugs (basiliximab or daclizumab) should be used unless it is contraindicated. ... - Medical News Today





New insights into how anti-rejection drug daclizumab helps MS ...  Mar 28, 2006
A research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into the role of the MS drug daclizumab (Zenapax) in the March ... - RxPG NEWS

MS drug works in surprise way  Mar 30, 2006
...team led by Bibiana Bielekova, director of the University of Cincinnati's Waddell Center for Multiple Sclerosis, looked at how the drug daclizumab works to ... - Cincinnati Enquirer

MS drug has promise, UC team reports  Mar 28, 2006
The team, led by Dr. Bibiana Bielekova researched the drug daclizumab (Zenapax), and its effectiveness on MS patients, because it has proven useful in treating ... - Cincinnati Business Courier

PDL BioPharma Announces Fourth Quarter and Full Year 2005 ...  Feb 27, 2006
The increase reflected expanded clinical trial efforts for Nuvion®, ularitide and daclizumab, manufacturing-related costs and additional personnel in these ... - Yahoo! News

Tysabri Events For Biogen Idec Overshadow Year-End Figures  Feb 17, 2006
28. Also in the pipeline, Biogen Idec has oral fumarate BG-12 in Phase II development for multiple sclerosis; daclizumab, for the same indication, which is ... - BioWorld Online (subscription),

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional